Sensitivity of c-erbB positive cells to a ligand toxin and its utility in purging breast cancer cells from peripheral blood stem cell (PBSC) collections

Stem Cells

Volumn 18, Issue 6, 2000, Pages 422-427

  Keir, Michelle ^a   Fiddes, Rod ^b   Biggs, James C ^a   Kearney, Phillip P ^a,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b Australian Maritime Engineering   (Australia)

^c Active Biotech Research AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NEU DIFFERENTIATION FACTOR; PSEUDOMONAS EXOTOXIN; RECOMBINANT DNA;

ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOGENESIS; ONCOGENE C ERB; PERIPHERAL BLOOD STEM CELL; STEM CELL TRANSPLANTATION;

PSEUDOMONAS; PSEUDOMONAS EXOTOXIN;

EID: 0033767012     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.18-6-422     Document Type: Article

References (27)

1. Breast cancer
2. Cyclophosphamide mobilization of peripheral blood stem cells for use in autologous transplantation after high-dose chemotherapy: Clinical results in patients with contaminated or hypocellular bone marrow
3. High-dose combination alkylating agents with autologous bone marrow support: A phase 1 trial
4. Cancer statistics, 1991
5. Tumor cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up
6. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
7. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
8. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
9. High dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: A 10 year experience
10. Purging marrow or peripheral blood stem cells for autografting
11. + hematopoietic progenitor cells
12. Recombinant toxins for cancer treatment
13. Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice
14. Engineering high affinity humanized anti-p185 (HER2)/anti-CD3 bispecific F(ab')(2) for efficient lysis of p185 (HER2) overexpressing tumour cells
15. The tyrosine kinase activity of the c-erbB-2 gene product (p185) is required for growth inhibition by anti-p 185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin
16. Targeted tumour killing via an intracellular antibody against erbB-2
17. EGF receptor and p185erbB-2 specific single chain antibody toxins differ in their cell killing activity on tumour cells expressing both receptor proteins
18. Identification of heregulin, a specific activator of p185erbB2
19. Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin
20. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG-PE40 ligand toxin in human breast cancer cells
21. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4
22. Preclinical testing of an anti-erbB2 recombinant toxin
23. Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients
24. A bivalent single chain antibody-toxin specific for ErbB-2 and the EGF receptor
25. Cofactor competition between ligand bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer
26. Tumor-antigen herogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease